US7700603B2
(en)
|
2003-12-15 |
2010-04-20 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
US7763609B2
(en)
|
2003-12-15 |
2010-07-27 |
Schering Corporation |
Heterocyclic aspartyl protease inhibitors
|
US7868000B2
(en)
|
2005-06-14 |
2011-01-11 |
Schering Corporation |
Aspartyl protease inhibitors
|
ES2436795T3
(es)
|
2005-06-14 |
2014-01-07 |
Merck Sharp & Dohme Corp. |
Inhibidores heterocíclicos de aspartil proteasa, preparación y uso de los mismos
|
CN103936690B
(zh)
|
2005-10-25 |
2016-06-08 |
盐野义制药株式会社 |
氨基二氢噻嗪衍生物
|
AR061264A1
(es)
|
2006-06-12 |
2008-08-13 |
Schering Corp |
Inhibidores de aspartil-proteasas derivados de pirimidina, composiciones farmaceuticas que los contienen y usos para tratar enfermedades cognitivas o neurodegenerativas, y como inhibidores del virus vih.
|
EP2151435A4
(en)
|
2007-04-24 |
2011-09-14 |
Shionogi & Co |
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
|
MX2009011498A
(es)
|
2007-04-24 |
2009-11-10 |
Shionogi & Co |
Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
|
RU2476431C2
(ru)
*
|
2008-01-18 |
2013-02-27 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Конденсированное производное аминодигидротиазина
|
JP2011518225A
(ja)
|
2008-04-22 |
2011-06-23 |
シェーリング コーポレイション |
Bace−1阻害剤としてのフェニル置換2−イミノ−3−メチルピロロピリミジノン化合物、組成物、およびそれらの使用
|
KR20130018370A
(ko)
|
2008-06-13 |
2013-02-20 |
시오노기세야쿠 가부시키가이샤 |
β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
|
AU2009277485B2
(en)
|
2008-07-28 |
2013-05-02 |
Eisai R&D Management Co., Ltd. |
Spiroaminodihydrothiazine derivatives
|
US8426447B2
(en)
*
|
2008-09-11 |
2013-04-23 |
Amgen Inc. |
Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
|
EP2332943B1
(en)
*
|
2008-09-30 |
2015-04-22 |
Eisai R&D Management Co., Ltd. |
Novel fused aminodihydrothiazine derivative
|
RU2503681C2
(ru)
*
|
2008-09-30 |
2014-01-10 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Новое конденсированное производное аминодигидротиазина
|
JPWO2010047372A1
(ja)
|
2008-10-22 |
2012-03-22 |
塩野義製薬株式会社 |
Bace1阻害活性を有する2−アミノピリミジン−4−オンおよび2−アミノピリジン誘導体
|
AR077277A1
(es)
*
|
2009-07-09 |
2011-08-17 |
Lilly Co Eli |
Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
|
GB0912778D0
(en)
*
|
2009-07-22 |
2009-08-26 |
Eisai London Res Lab Ltd |
Fused aminodihydro-oxazine derivatives
|
GB0912777D0
(en)
|
2009-07-22 |
2009-08-26 |
Eisai London Res Lab Ltd |
Fused aminodihydropyrimidone derivatives
|
UY32799A
(es)
|
2009-07-24 |
2011-02-28 |
Novartis Ag |
Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
|
UA108363C2
(uk)
|
2009-10-08 |
2015-04-27 |
|
Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
|
US8563543B2
(en)
|
2009-10-08 |
2013-10-22 |
Merck Sharp & Dohme Corp. |
Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
EP2485920B1
(en)
|
2009-10-08 |
2016-04-27 |
Merck Sharp & Dohme Corp. |
Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
|
WO2011044184A1
(en)
|
2009-10-08 |
2011-04-14 |
Schering Corporation |
Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use
|
US20120238557A1
(en)
*
|
2009-11-13 |
2012-09-20 |
Shionogi & Co., Ltd. |
Aminothiazine or aminooxazine derivative having amino linker
|
US8870950B2
(en)
|
2009-12-08 |
2014-10-28 |
Mitral Tech Ltd. |
Rotation-based anchoring of an implant
|
US20120245154A1
(en)
|
2009-12-09 |
2012-09-27 |
Shionogi & Co., Ltd. |
Substituted aminothiazine derivative
|
US7964594B1
(en)
|
2009-12-10 |
2011-06-21 |
Hoffmann-La Roche Inc. |
Amino oxazine derivatives
|
UA103272C2
(uk)
|
2009-12-11 |
2013-09-25 |
Ф. Хоффманн-Ля Рош Аг |
2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
|
WO2011071109A1
(ja)
|
2009-12-11 |
2011-06-16 |
塩野義製薬株式会社 |
アミノ基を有する縮合ヘテロ環化合物
|
WO2011071135A1
(ja)
|
2009-12-11 |
2011-06-16 |
塩野義製薬株式会社 |
オキサジン誘導体
|
PE20121640A1
(es)
|
2009-12-31 |
2012-12-17 |
Novartis Ag |
Derivados de pirazina como inhibidores de bace
|
US8883782B2
(en)
|
2010-03-15 |
2014-11-11 |
Amgen Inc. |
Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
|
JP5584352B2
(ja)
|
2010-03-15 |
2014-09-03 |
アムジエン・インコーポレーテツド |
β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
|
US8673894B2
(en)
|
2010-05-07 |
2014-03-18 |
Hoffmann-La Roche Inc. |
2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
|
WO2012006953A1
(en)
|
2010-07-13 |
2012-01-19 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
US8921363B2
(en)
|
2010-08-05 |
2014-12-30 |
Amgen Inc. |
Derivatives of 1 H-isoindol-3-amine, 1 H-iso-aza-indol-3amine, 3,4-dihydroisoquinolin-1-amine, and 1,4-dihydroisoquinolin-3-amine as beta-secretase inhibitors
|
EP2634188A4
(en)
|
2010-10-29 |
2014-05-07 |
Shionogi & Co |
FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
|
US8927721B2
(en)
|
2010-10-29 |
2015-01-06 |
Shionogi & Co., Ltd. |
Naphthyridine derivative
|
EP2643325A1
(en)
|
2010-11-23 |
2013-10-02 |
Amgen Inc. |
Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
|
GB201100181D0
(en)
*
|
2011-01-06 |
2011-02-23 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
CN103429589A
(zh)
|
2011-01-12 |
2013-12-04 |
诺瓦提斯公司 |
噁嗪衍生物及其在治疗神经障碍中的用途
|
US8524897B2
(en)
|
2011-01-12 |
2013-09-03 |
Novartis Ag |
Crystalline oxazine derivative
|
CA2824220C
(en)
|
2011-01-13 |
2020-09-01 |
Novartis Ag |
Novel heterocyclic derivatives and their use in the treatment of neurological disorders
|
SG10201601516QA
(en)
|
2011-01-21 |
2016-03-30 |
Eisai R&D Man Co Ltd |
Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
|
GB201101139D0
(en)
*
|
2011-01-21 |
2011-03-09 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
GB201101140D0
(en)
|
2011-01-21 |
2011-03-09 |
Eisai Ltd |
Fused aminodihydrothiazine derivatives
|
EP2673279A1
(en)
|
2011-02-07 |
2013-12-18 |
Amgen Inc. |
5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
|
US8404680B2
(en)
|
2011-02-08 |
2013-03-26 |
Hoffmann-La Roche Inc. |
N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
|
US8962859B2
(en)
|
2011-02-15 |
2015-02-24 |
Amgen Inc. |
Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
|
US8815841B2
(en)
|
2011-02-18 |
2014-08-26 |
Hoffmann-La Roche Inc. |
1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
|
US9221839B2
(en)
|
2011-04-07 |
2015-12-29 |
Merck Sharp & Dohme Corp. |
C5-C6 oxacyclic-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
|
EP2694521B1
(en)
|
2011-04-07 |
2015-11-25 |
Merck Sharp & Dohme Corp. |
Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
|
US8754075B2
(en)
|
2011-04-11 |
2014-06-17 |
Hoffmann-La Roche Inc. |
1,3-oxazines as BACE1 and/or BACE2 inhibitors
|
WO2012147763A1
(ja)
|
2011-04-26 |
2012-11-01 |
塩野義製薬株式会社 |
オキサジン誘導体およびそれを含有するbace1阻害剤
|
US9181236B2
(en)
|
2011-08-22 |
2015-11-10 |
Merck Sharp & Dohme Corp. |
2-spiro-substituted iminothiazines and their mono-and dioxides as bace inhibitors, compositions and their use
|
EP2751116B1
(en)
|
2011-08-31 |
2016-10-12 |
Pfizer Inc |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
WO2013044092A1
(en)
|
2011-09-21 |
2013-03-28 |
Amgen Inc. |
Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
|
CN104066727B
(zh)
|
2012-01-26 |
2019-04-26 |
霍夫曼-拉罗奇有限公司 |
氟甲基-5,6-二氢-4h-[1,3]噁嗪类
|
US8338413B1
(en)
|
2012-03-07 |
2012-12-25 |
Novartis Ag |
Oxazine derivatives and their use in the treatment of neurological disorders
|
JO3143B1
(ar)
*
|
2012-04-03 |
2017-09-20 |
Lilly Co Eli |
مركبات تتراهيدرو بيرولو ثيازين
|
US9227942B2
(en)
*
|
2012-04-27 |
2016-01-05 |
Eisai R&D Management Co., Ltd. |
Method for producing 5-(difluoromethyl)pyrazine-2-carboxylic acid and production intermediate thereof
|
ES2585262T3
(es)
|
2012-05-04 |
2016-10-04 |
Pfizer Inc |
Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
|
WO2014015125A1
(en)
|
2012-07-19 |
2014-01-23 |
Eisai R&D Management Co., Ltd. |
Fused aminodihydrothiazine derivative salts and uses thereof
|
GB201212871D0
(en)
|
2012-07-20 |
2012-09-05 |
Eisai Ltd |
Novel compounds
|
EP2897964A1
(en)
|
2012-09-20 |
2015-07-29 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
|
WO2014065434A1
(en)
|
2012-10-24 |
2014-05-01 |
Shionogi & Co., Ltd. |
Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
|
JP6243921B2
(ja)
|
2012-10-26 |
2017-12-06 |
イーライ リリー アンド カンパニー |
Bace阻害剤
|
US9725469B2
(en)
|
2012-11-15 |
2017-08-08 |
Amgen, Inc. |
Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
|
CA2893256A1
(en)
|
2012-12-11 |
2014-06-19 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
EP2935282A1
(en)
*
|
2012-12-19 |
2015-10-28 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
WO2014120658A1
(en)
|
2013-01-29 |
2014-08-07 |
Amgen Inc. |
Fused multicyclic 3-amino-5,6-dihydro-2h-1,4-thiazine derivatives and their use as beta-secretase inhibitors
|
EP2956458B1
(en)
|
2013-02-13 |
2017-08-09 |
Pfizer Inc |
Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
US9233981B1
(en)
*
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
WO2014134341A1
(en)
|
2013-03-01 |
2014-09-04 |
Amgen Inc. |
Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
EP2964644B1
(en)
|
2013-03-08 |
2018-12-26 |
Amgen, Inc. |
Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
TWI593692B
(zh)
*
|
2013-03-12 |
2017-08-01 |
美國禮來大藥廠 |
四氫吡咯并噻嗪化合物
|
WO2014166906A1
(en)
|
2013-04-11 |
2014-10-16 |
F. Hoffmann-La Roche Ag |
Bace1 inhibitors
|
TWI639607B
(zh)
|
2013-06-18 |
2018-11-01 |
美國禮來大藥廠 |
Bace抑制劑
|
US9096615B2
(en)
|
2013-07-30 |
2015-08-04 |
Amgen Inc. |
Bridged bicyclic amino thiazine dioxide compounds as inhibitors of beta-secretase and methods of use thereof
|
TWI684452B
(zh)
*
|
2014-03-14 |
2020-02-11 |
美國禮來大藥廠 |
胺基噻嗪化合物
|
EA030085B1
(ru)
|
2014-04-10 |
2018-06-29 |
Пфайзер Инк. |
2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
|
MX2017001794A
(es)
|
2014-08-08 |
2017-06-29 |
Amgen Inc |
Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
|
TWI570127B
(zh)
*
|
2014-09-15 |
2017-02-11 |
美國禮來大藥廠 |
結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
|
TWI599358B
(zh)
*
|
2014-09-16 |
2017-09-21 |
美國禮來大藥廠 |
組合療法
|
US10117876B2
(en)
*
|
2014-10-10 |
2018-11-06 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical composition of fused aminodihydrothiazine derivative
|
AR103406A1
(es)
*
|
2015-01-30 |
2017-05-10 |
Lilly Co Eli |
Sal de tosilato
|
AR103680A1
(es)
*
|
2015-02-23 |
2017-05-24 |
Lilly Co Eli |
Inhibidores selectivos de bace1
|
CN107257795A
(zh)
|
2015-03-19 |
2017-10-17 |
伊莱利利公司 |
选择性bace1抑制剂
|
AR104241A1
(es)
*
|
2015-04-29 |
2017-07-05 |
Lilly Co Eli |
Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
|
WO2017024180A1
(en)
|
2015-08-06 |
2017-02-09 |
Amgen Inc. |
Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
|
WO2017051276A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
|
JP2018534251A
(ja)
|
2015-09-24 |
2018-11-22 |
ファイザー・インク |
Bace阻害剤として有用なn−[2−(3−アミノ−2,5−ジメチル−1,1−ジオキシド−5,6−ジヒドロ−2h−1,2,4−チアジアジン−5−イル)−1,3−チアゾール−4−イル]アミド
|
JP2018531924A
(ja)
|
2015-09-24 |
2018-11-01 |
ファイザー・インク |
テトラヒドロピラノ[3,4−d][1,3]オキサジン誘導体、およびbace阻害剤としてのその使用
|
WO2017070089A1
(en)
|
2015-10-19 |
2017-04-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN115322188A
(zh)
|
2015-10-30 |
2022-11-11 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
EP4141002A1
(en)
|
2015-11-19 |
2023-03-01 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US10329291B2
(en)
|
2015-12-04 |
2019-06-25 |
Merck Sharp & Dohme Corp. |
C5-C6-carbocyclic fused iminothiadiazine dioxides as BACE inhibitors, compositions, and their use
|
MA44075A
(fr)
*
|
2015-12-17 |
2021-05-19 |
Incyte Corp |
Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
|
PL3394033T3
(pl)
|
2015-12-22 |
2021-05-31 |
Incyte Corporation |
Związki heterocykliczne jako immunomodulatory
|
HUE059065T2
(hu)
|
2015-12-23 |
2022-10-28 |
Neurocrine Biosciences Inc |
Szintetikus eljárás (S)-(2R,3R,11BR)-3-izobutil-9,10-dimetoxi-2,3,4,6,7,11B-hexahidro-1H-pirido [2,1-A]izokinolin-2-il-2-amino-3-metilbutanoát-di(4-metilbenzolszulfonát) elõállítására
|
AR107774A1
(es)
*
|
2016-03-16 |
2018-05-30 |
Lilly Co Eli |
Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
|
TW201808950A
(zh)
|
2016-05-06 |
2018-03-16 |
英塞特公司 |
作為免疫調節劑之雜環化合物
|
MA45116A
(fr)
|
2016-05-26 |
2021-06-02 |
Incyte Corp |
Composés hétérocycliques comme immunomodulateurs
|
MX2018016273A
(es)
|
2016-06-20 |
2019-07-04 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores.
|
EP3484866B1
(en)
|
2016-07-14 |
2022-09-07 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2018034977A1
(en)
*
|
2016-08-18 |
2018-02-22 |
Eli Lilly And Company |
Combination therapy of bace-1 inhibitor and anti-n3pglu abeta antibody
|
MA46045A
(fr)
|
2016-08-29 |
2021-04-28 |
Incyte Corp |
Composés hétérocycliques utilisés comme immunomodulateurs
|
TWI669119B
(zh)
|
2016-10-21 |
2019-08-21 |
美國禮來大藥廠 |
組合療法
|
MX2019004872A
(es)
*
|
2016-10-27 |
2019-10-30 |
Eisai R&D Man Co Ltd |
Composicion que comprende un anticuerpo de protofibrilla anti-abeta y un inhibidor de beta-secretasa bace1 para el tratamiento de enfermedad de alzheimer.
|
CA3047285A1
(en)
|
2016-12-15 |
2018-06-21 |
Amgen Inc. |
Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use
|
MX2019007104A
(es)
|
2016-12-15 |
2019-11-05 |
Amgen Inc |
Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
|
CA3047288A1
(en)
|
2016-12-15 |
2018-06-21 |
Amgen Inc. |
Thiazine derivatives as beta-secretase inhibitors and methods of use
|
AU2017376441B2
(en)
|
2016-12-15 |
2021-10-14 |
Amgen Inc. |
Oxazine derivatives as beta-secretase inhibitors and methods of use
|
MX2019007103A
(es)
|
2016-12-15 |
2019-11-05 |
Amgen Inc |
Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
|
MD3558990T2
(ro)
|
2016-12-22 |
2023-02-28 |
Incyte Corp |
Derivați tetrahidro imidazo[4,5-c]piridină ca inductori de internalizare a PD-L1
|
ES2899402T3
(es)
|
2016-12-22 |
2022-03-11 |
Incyte Corp |
Derivados de piridina como inmunomoduladores
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
CN110582493B
(zh)
|
2016-12-22 |
2024-03-08 |
因赛特公司 |
作为免疫调节剂的苯并噁唑衍生物
|
CN107892697B
(zh)
*
|
2016-12-26 |
2020-11-03 |
郑州泰基鸿诺医药股份有限公司 |
一种[1,3]噻嗪-2-胺类化合物及应用,药物组合物
|
JP7199361B2
(ja)
|
2017-01-27 |
2023-01-05 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
特定のvmat2インヒビターを投与するための方法
|
CN111372567B
(zh)
|
2017-09-21 |
2024-03-15 |
纽罗克里生物科学有限公司 |
高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
SG11202003194YA
(en)
|
2017-10-10 |
2020-05-28 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
SG11202009440WA
(en)
|
2018-03-30 |
2020-10-29 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
DK3790877T3
(da)
|
2018-05-11 |
2023-04-24 |
Incyte Corp |
Tetrahydro-imidazo[4,5-c]pyridinderivater som pd-l1-immunmodulatorer
|
EP3826674A2
(en)
|
2018-07-24 |
2021-06-02 |
Eisai R&D Management Co., Ltd. |
Methods of treatment and prevention of alzheimer's disease
|
EP3836926A4
(en)
|
2018-08-15 |
2022-05-04 |
Neurocrine Biosciences, Inc. |
METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
|
CN109748878A
(zh)
*
|
2019-01-21 |
2019-05-14 |
江苏中旗科技股份有限公司 |
一种甲磺草胺关键中间体苯连三唑啉酮衍生物的制备方法
|
WO2021030162A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
US11401279B2
(en)
|
2019-09-30 |
2022-08-02 |
Incyte Corporation |
Pyrido[3,2-d]pyrimidine compounds as immunomodulators
|
TW202120504A
(zh)
|
2019-11-11 |
2021-06-01 |
美商英塞特公司 |
Pd-1/pd-l1 抑制劑之鹽及結晶型
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之結晶形式
|
WO2022099018A1
(en)
|
2020-11-06 |
2022-05-12 |
Incyte Corporation |
Process of preparing a pd-1/pd-l1 inhibitor
|
AU2021373044A1
(en)
|
2020-11-06 |
2023-06-08 |
Incyte Corporation |
Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof
|